Plant-Derived TUDCA Synthesis via Sitosterol
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for synthesizing cholic acid derivatives, particularly TUDCA, are inefficient and often result in contamination with animal-derived impurities, posing risks of pathogen contamination and difficulty in separating closely related analogs and isomers.
Innovation Solution
Development of methods to produce non-animal derived TUDCA with exceptional purity, utilizing a taurine conjugate of ursodeoxycholic acid with a specific δ13C signature corresponding to plant-derived material, and employing novel crystalline forms and salts of TUDCA to minimize impurities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If animal-derived bile acids are used as starting material, then TUDCA can be produced through conventional synthesis, but the product is contaminated with animal-derived impurities and pathogens such as prions
Solution Approach 1:
The patent extracts and eliminates the harmful animal-derived component by using plant-derived sterols (specifically sitosterol from vegetable sources) as the starting material instead of animal bile acids. This substitution removes the source of prion and pathogen contamination while maintaining the ability to produce TUDCA through chemical synthesis.
Solution Approach 2:
The patent changes the source parameter of the starting material from animal origin to plant origin. By using plant-derived sterols with specific physical and chemical properties, the synthesis pathway produces TUDCA free from animal-derived contaminants while maintaining product efficacy.
2Productivity
If conventional synthesis methods are used, then TUDCA can be manufactured, but closely related analogs and isomers cannot be easily separated
Solution Approach 1:
The patent employs a multi-step synthesis pathway that breaks down the complex transformation into discrete stages: (1) conversion of plant sterols to cholic acid derivatives, (2) specific hydroxylation at C-7 position, (3) conjugation with taurine. This segmentation allows for better control and separation at each stage, preventing isomer formation and facilitating purification.
Solution Approach 2:
The patent uses specific intermediate compounds (7-ketolithocholic acid and its derivatives) as mediators in the synthesis pathway. These intermediates have distinct chemical properties that enable selective reactions and easier separation from isomers, acting as stepping stones that simplify the overall purification process.
3Reliability
If multiple reaction steps are employed to produce TUDCA, then the synthesis can be completed, but the process becomes cumbersome and inefficient
Solution Approach 1:
The patent combines multiple reaction steps into integrated synthesis pathways. For example, the hydroxylation and conjugation steps are performed in sequence without complete isolation and characterization of intermediates, reducing the number of separate operations. The use of plant-derived starting materials also merges the advantages of renewable resources with efficient synthesis.
Solution Approach 2:
The patent optimizes reaction parameters (temperature, pH, catalysts, solvent systems) at each stage to maximize yield and minimize side reactions. By carefully controlling these parameters, the multi-step synthesis becomes more efficient and less cumbersome, reducing the need for extensive purification steps.
Data Source
AI summary
Methods of making cholic acid derivatives, particularly TUDCA, preferably from non-animal sources, having exceptional purity and therapeutic utility.